Steven H Bernstein

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. pmc The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives
    Steven H Bernstein
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Blood 119:3321-9. 2012
  2. doi request reprint Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group
    Steven H Bernstein
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 27:114-9. 2009
  3. ncbi request reprint The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway
    Denise M Ray
    Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Exp Hematol 34:1202-11. 2006
  4. pmc Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide
    Jolanta Skalska
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 4:e8115. 2009
  5. pmc Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells
    Tatiana M Garcia-Bates
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Clin Cancer Res 14:6414-25. 2008
  6. pmc Peroxisome proliferator-activated receptor gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and survival
    Tatiana M Garcia-Bates
    Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Cancer Immunol Immunother 58:1071-83. 2009
  7. ncbi request reprint Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells
    Elizabeth P Ryan
    Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Immunol 120:76-90. 2006
  8. pmc High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era
    Makiko Ban-Hoefen
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Lymphoma 53:830-5. 2012
  9. pmc Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of non-Hodgkin lymphoma
    Lynn F Sniderhan
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Exp Hematol 37:1295-309. 2009
  10. pmc Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiation
    Shannon P Hilchey
    James P Wilmot Cancer Center, Lymphoma Biology Program, University of Rochester Medical Center, Rochester, NY, USA
    Blood 118:3591-602. 2011

Collaborators

Detail Information

Publications26

  1. pmc The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives
    Steven H Bernstein
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Blood 119:3321-9. 2012
    ..Together, these findings suggest that Lon inhibition plays a contributory role in CDDO-induced lymphoma cell death, and support the concept that mitochondrial Lon is a novel anticancer drug target...
  2. doi request reprint Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group
    Steven H Bernstein
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 27:114-9. 2009
    ..To investigate the incidence, natural history, and risk factors predictive of CNS relapse in patients with de novo aggressive lymphomas and to evaluate the efficacy of CNS prophylaxis in patients with initial bone marrow (BM) involvement...
  3. ncbi request reprint The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway
    Denise M Ray
    Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Exp Hematol 34:1202-11. 2006
    ..Herein, we investigated the triterpenoid CDDO, a PPAR gamma ligand, for its potential as an anticancer agent on human diffuse large B-cell lymphoma (DLBCL) cells...
  4. pmc Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide
    Jolanta Skalska
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 4:e8115. 2009
    ..Given recent data to suggest that the redox status of extracellular protein thiol groups (i.e. exofacial thiols) effects cell behavior, we hypothesized that redox active anti-cancer agents would modulate exofacial protein thiols...
  5. pmc Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells
    Tatiana M Garcia-Bates
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Clin Cancer Res 14:6414-25. 2008
    ..To further understand the role of PPARgamma, we examined the functional consequences of its overexpression in human multiple myeloma...
  6. pmc Peroxisome proliferator-activated receptor gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and survival
    Tatiana M Garcia-Bates
    Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Cancer Immunol Immunother 58:1071-83. 2009
    ..These findings further suggest the potential of PPARgamma as a therapeutic target for B cell malignancy...
  7. ncbi request reprint Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells
    Elizabeth P Ryan
    Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Immunol 120:76-90. 2006
    ..It will therefore be important to evaluate drugs that inhibit Cox-2 as potential therapeutic agents in B-CLL in vivo...
  8. pmc High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era
    Makiko Ban-Hoefen
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Lymphoma 53:830-5. 2012
    ..However, patients exposed to rituximab pre-transformation appear to have inferior HD-ASCT outcomes, and thus may benefit from novel conditioning and maintenance regimens in the setting of HD-ASCT...
  9. pmc Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of non-Hodgkin lymphoma
    Lynn F Sniderhan
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Exp Hematol 37:1295-309. 2009
    ..In order to analyze the potential contribution of neurotrophin signaling to lymphoma cell survival, we investigated the role of a neurotrophin axis in promoting survival and proliferation of non-Hodgkin lymphoma (NHL) cells...
  10. pmc Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiation
    Shannon P Hilchey
    James P Wilmot Cancer Center, Lymphoma Biology Program, University of Rochester Medical Center, Rochester, NY, USA
    Blood 118:3591-602. 2011
    ....
  11. pmc Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era
    Sarah F Keller
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 18:640-7. 2012
    ..Our results emphasize the importance of long-term follow-up for both toxicity and recurrence, and have important implications in defining success of posttransplantation maintenance strategies...
  12. pmc Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
    Shannon P Hilchey
    James P Wilmot Cancer Center, Aab Institute of Biomedical Sciences, and Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester, NY 14642, USA
    Blood 113:3809-12. 2009
    ..Our data thus provide "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active FL-specific cellular response...
  13. pmc Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness
    Shannon P Hilchey
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Immunol 183:6157-66. 2009
    ..In addition, these studies suggest that the A(2A/B) AR as well as CD39 are novel pharmacological targets for augmenting cancer immunotherapy...
  14. ncbi request reprint CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism
    Denise M Ray
    Department of Environmental Medicine, The Lung Biology and Disease Program, University of Rochester Medical Center, School of Medicine and Dentistry, NY 14642, USA
    J Immunol 174:4060-9. 2005
    ..Moreover, the ability of PPARgamma agonists to kill malignant B lineage cells has implications for their use as anti-B lymphoma agents...
  15. pmc The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, NYm, USA
    Blood 117:2807-12. 2011
    ..On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534...
  16. ncbi request reprint Use of CFSE to monitor ex vivo regulatory T-cell suppression of CD4+ and CD8+ T-cell proliferation within unseparated mononuclear cells from malignant and non-malignant human lymph node biopsies
    Shannon P Hilchey
    James P Wilmot Cancer Center, Lymphoma Biology Program, University of Rochester Medical Center, Rochester, New York, USA
    Immunol Invest 36:629-48. 2007
    ....
  17. pmc CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells
    Jennifer Huggins
    Department of Pathology, James P Wilmot Cancer Center, University of Rochester Medical Center, NY 14642, USA
    Blood 109:1611-9. 2007
    ..In addition to its immunologic significance, this system should be a valuable method to interrogate the antigenic specificity of naive B cells...
  18. ncbi request reprint The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore
    Paul S Brookes
    Department of Anesthesiology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Cancer Res 67:1793-802. 2007
    ....
  19. pmc Mesenchymal stromal cells support the viability and differentiation of follicular lymphoma-infiltrating follicular helper T-cells
    Michael T Brady
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
    PLoS ONE 9:e97597. 2014
    ..Given that the balance of TFH and TFR populations likely dictate, in part, the biology of this disease, our data support the potential for targeting MSCs as a therapeutic strategy. ..
  20. pmc Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies
    Tatiana M Garcia-Bates
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    PPAR Res 2008:834612. 2008
    ..Understanding the diverse properties of PPARgamma ligands is crucial for the development of new therapeutic approaches for hematological malignancies...
  21. ncbi request reprint More than structural cells, fibroblasts create and orchestrate the tumor microenvironment
    Carolyn J Baglole
    Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, and Lymphoma Biology Program, James P Wilmot Cancer Center, Rochester, New York 14642, USA
    Immunol Invest 35:297-325. 2006
    ..This review will highlight the emerging role of the complex fibroblastic stroma in establishing a microenvironment supporting malignant transformation, tumor growth and attenuation of host anti-tumor immune responses...
  22. doi request reprint A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection
    Gordon L Phillips
    Hematology Oncology, University of Rochester Medical Center, James P Wilmot Cancer Center, Strong Memorial Hospital, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 17:1033-42. 2011
    ..A Phase II trial is planned...
  23. ncbi request reprint Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells
    Shannon P Hilchey
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Immunol 178:4051-61. 2007
    ..Lastly, we demonstrate that inhibition of TGF-beta signaling partially restores FLN T cell proliferation suggesting a mechanistic role for TGF-beta in FLN T(R)-mediated suppression...
  24. ncbi request reprint Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands
    Denise M Ray
    The Lung Biology and Disease Program, Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    Clin Immunol 113:203-13. 2004
    ..These new findings support that PPARgamma ligands may represent a novel therapy for multiple myeloma...
  25. ncbi request reprint Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production
    Elizabeth P Ryan
    Department of Environmental Medicine, Lung Biology and Disease Program, University of Rochester School of Medicine and Dentistry, NY, USA
    J Immunol 174:2619-26. 2005
    ..Use of NSAIDs may therefore influence autoantibody production in autoimmune diseases and may dampen humoral immunity in response to antigenic challenge/vaccination...
  26. ncbi request reprint Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Richard I Fisher
    University of Rochester, James P Wilmot Cancer Center, Rochester, USA
    J Clin Oncol 24:4867-74. 2006
    ..Evaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of bortezomib treatment in patients with relapsed or refractory mantle cell lymphoma (MCL)...